Treatment Stories
651 articles
In the Fight Against Pancreatic Cancer, Knowledge Is Power
Oncologist Allyson Ocean, M.D., introduces Let’s Win, an interactive website for pancreatic cancer patients to learn about new treatments.
Steven Merlin and Davi D’Agostino Team Up to Help Others
Pancreatic cancer patient advocates Steven Merlin and Davi D’Agostino have joined to pool expertise and information for other patients.
Comparing Chemotherapy Before with Chemotherapy After Pancreatic Cancer Surgery
Researchers are comparing effectiveness of chemotherapy before surgery (neoadjuvant) with chemotherapy after surgery (adjuvant).
Pancreatic Cancer and Drug Interactions: What You Need to Know
Pharmacist Trevor Christ emphasizes the importance of sharing your medication list with your medical team and pharmacist.
PARP Inhibitor as Maintenance for Pancreatic Cancer Patients with BRCA1, BRCA2, or PALB2 Mutations
A new clinical trial tests a PARP inhibitor as maintenance treatment for pancreatic cancer patients with BRCA1/2 or PALB2 mutations.
Mental Health and Pancreatic Cancer
Dr. William Breitbart provides tips for your mental health during pancreatic cancer treatment, and an explanation of who can provide help.
Calming the Storm of a Pancreatic Cancer Diagnosis
Social worker Angie Heller and caregiver Richard Cohen describe ways patients and loved ones can focus on what matters most after diagnosis.
Testing Standard Treatment Plus an Antibody to Shrink Pancreatic Tumors
Researchers are testing whether adding a monoclonal antibody to standard chemotherapy will make locally advanced pancreatic cancer qualify for surgery.
Using Molecular Tumor Profiling to Determine the Best Pancreatic Cancer Treatment
A clinical trial looks at whether molecular subtyping of tumors is effective in determining the best pancreatic cancer treatment.
A Maintenance Trial for Patients with BRCA or PALB2 Mutations
A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.